Physician profile
Ricardo E Saca
NPI 1619072774
$4,740.48
in general payments reported to CMS, 2019-2025
18 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $504 · 2021: $426 · 2022: $522 · 2023: $475 · 2024: $772 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.56 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $756.34 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $623.90 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbott Laboratories | $424.66 | 2019-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $410.32 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $335.61 | 2019-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.21 | 2023-2025 | Caplyta |
| Amgen INC. | $222.89 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $190.14 | 2020-2022 | |
| Alkermes, INC. | $144.61 | 2024-2025 | Aristada, Aristada Initio |
| Allergan, INC. | $74.20 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $67.50 | 2019 | |
| Almatica Pharma LLC | $54.15 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $48.18 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $45.98 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.96 | 2025 | Cobenfy |
| Bausch Health US, LLC | $26.79 | 2020 | |
| Lundbeck LLC | $19.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Saca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.